Study of the effect of myrtus communis L.extract on Alzheimer's disease
Phase 3
Completed
- Conditions
- Alzheimer's disease.Other degenerative diseases of the nervous systemG30-G32
- Registration Number
- IRCT20170702034861N8
- Lead Sponsor
- Kerman University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Age 50 to 85 years
MMSE score between 16 and 24
No drug abuse and alcohol dependence
Not taking anticoagulants
Ability to answer questions and no mental problems
Exclusion Criteria
depression
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method • Cognitive status of patients. Timepoint: Before and after 4 weeks of intervention. Method of measurement: Mini-Mental State Exam (MMSE) and Clinical Dementia Rating (CDR)questionnair.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of myrtus communis L. extract may influence Alzheimer's disease progression?
How does myrtus communis L. extract compare to standard-of-care treatments for mild to moderate Alzheimer's disease?
Are there specific biomarkers that predict response to myrtus communis L. extract in patients with G30-G32 degenerative diseases?
What are the potential adverse events associated with standardized hydroalcoholic myrtus communis L. extract in Alzheimer's treatment?
What related compounds or combination therapies show promise in treating Alzheimer's disease alongside myrtus communis L. extract?